



**GROWTH ACCELERATES TO 17.6% IN Q3 2012, WITH SALES TOTALLING
€366.4 MILLION**

2012 SALES TARGET OF €1,425 MILLION REITERATED

Puteaux, 14th November 2012

ORPEA, leading European player in Long-Term Care (nursing homes), Post-Acute Care and Psychiatric Care, today announced its revenues for the third quarter of 2012 to 30th September.

In €m IFRS	Quarterly			9-months		
	Q3 2012	Q3 2011	Var.	2012	2011	Var.
France <i>% of total sales</i>	307.2 84%	274.3 88%	+12.0%	909.1 86%	800.0 88%	+13.6%
International <i>% of total sales</i>	59.2 16%	37.4 12%	+58.4%	142.1 14%	105.9 12%	+34.2%
Belgium	34.7	17.4		71.1	51.1	
Spain	12.1	7.9		36.8	23.0	
Italy	8.7	8.0		22.9	20.0	
Switzerland	3.7	4.0		11.3	11.8	
Total sales <i>Organic growth¹</i>	366.4	311.7	+17.6% +7.8%	1 051.2	905.9	+16.0% +8.3%

Yves Le Masne, CEO of ORPEA, comments: *“The growth momentum achieved by ORPEA since the beginning of the year has continued and even accelerated during the third quarter. Sales advanced by 17.6% on the back of further brisk organic growth (7.8%) and a strong increase in international markets (58.4%) thanks in particular to the successful integration of Artevida in Spain and of Medibelge in Belgium.*

¹ Organic growth is the result of the following factors: creations of new facilities, extensions to or restructuring of existing facilities, as well as changes in occupancy rates and daily rates. Organic growth is analysed facility by facility. Growth incorporates improvements in sales compared to the previous equivalent period, for recently-acquired facilities.

Organic growth, which reached 8.3% over the first nine months of the year, was again underpinned by:

- *a high occupancy rate at mature facilities in all the European markets;*
- *the ramp-up of facilities opened recently in strategic locations and offering a high standard of quality;*
- *the opening of close to 900 new beds during the quarter, representing around ten facilities, lifting the total number opened since the beginning of 2012 to 1,900.*

Through these accomplishments, ORPEA continues its commitment to the local economy, creating around 1,000 jobs since the beginning of the year.

With sales growth running at 16.0% over the first nine months of the year, ORPEA is confident in its ability to meet its full-year sales target of €1,425 million in 2012, together with improvement in its margins and cash flow.

Looking ahead to 2013 and subsequent years, ORPEA is very confident that it will be able to achieve solid growth in its sales and margins by tapping its pipeline of close to 8,000 beds and structural factors, including the ageing of the population.”

**Next press release: revenues for 2012 full-year,
13th February 2013, before market**

About ORPEA (www.orpea-corp.com)

Listed on Euronext Paris since April 2002 and a member of the Deferred Settlement Service, the ORPEA group is the leading European player in the Long-Term Care and Post-Acute Care sectors.

At 31 July 2012, the Group had a unique European network of healthcare facilities with 38,348 beds (33,317 of them operational) at over 410 sites, including:

- 28,819 beds in France: 25,340 operational (including 2,296 being renovated) + 3,479 under construction, at 333 facilities,
- 9,529 beds in Europe (Spain, Belgium, Italy and Switzerland): 7,977 operational (including 754 being renovated) + 1,552 under construction, at 77 facilities.

Listed on Euronext Paris Compartment of NYSE Euronext
Member of the **CAC Mid 60** and **SBF 120** indices - Member of the **SRD**
ISIN: FR0000184798 - Reuters: **ORP.PA** - Bloomberg: **ORP FP**



Media Relations:

PUBLICIS CONSULTANTS

Florence Marin

Tel: +33 (0)1 44 82 45 17

Email: florence.marin@consultants.publicis.fr

Investor Relations:

ORPEA

Yves Le Masne
CEO

Steve Grobet
Investor Relations Officer
Tel: +33 (0)1 47 75 74 66
Email: ats.grobet@orpea.net

NewCap.

Dusan Oresansky / Emmanuel Huynh
Tel: +33 (0)1 44 71 94 94
orpea@newcap.fr